The Role of Secondary Surgery in Recurrent Ovarian Cancer

Table 1

Published results on secondary cytoreduction for recurrent ovarian cancer.

Reference	𝑛	Definition used	Cytoreduced (%)	Median survival after secondary surgery
				(months)
Berek [3]	21	RD<o>1.5 cm;	6/21 (29); 15/21 (71)	<1.5, (20); >1.5 (5) 𝑃<0.01
Morris [6]	30	NVD; RD<o>2 cm	9/30 (30); 8/30 (27); 13/30 (43)	<2 (18.8); > 2(13.3) ns
Janicke [7]	28	NVD; RD<o> 2 cm	14/28 (50); 12/28 (43); 2/28 (7)	NVD, (29); RD, (9) 𝑃=0.0000
Segna [8]	100	RD<o>2 cm	61/100 (61); 39/100 (39)	<2,(27.1); >2, (9) 𝑃=0.0001
			3/5 stage I (60);
Pecorelli [9]	270	NVD; RD RD<o>2 cm	2/5 stage I (40);	<2 (20); >2 (12) 𝑃=0.045
			13/22 stage III (58);
			9/22 stage III ( 41)
Vaccarello [10]	57	RD<o>0.5 cm	38/57 (67); 23/38	<0.5, NYR; >0.5 (23)
Cormio [11]	21	NVD; no cytoreduction	15/21 (71); 6/21 (25)	NVD, (32); RD (9) 𝑃=0.029)
Gadducci [12]	30	NVD RD<o>2 cm	17/30 (57); 8/30 (27); 5/30 (17)	NVD (37); RD (19) 𝑃=0.04
Eisenkop [13]	106	NVD; RD<o>2 cm	87/106 (82); 3/106 (3); 16/106 (15)	NVD (44.4); RD (19.3) 𝑃=0.0007
Munkarah [14]	25	NVD; RD<o>2 cm	12/25 (48); 6/25 (24); 7/25 (28)	NVD (56.9); RD (25.1) 𝑃=0.08
Tay [15]	46	NVD; RD	19/46 (41); 27/46 (59)	NVD (38); RD (11) 𝑃=0.002
Zang [16]	107	NVD; RD<o>1 cm	11/107 (10); 61/107 (57); 35/107 (33)	NVD nyr; RD < 1 (26); >1(14.5)
Onda [17]	44	NVD; RD<o>1 cm	26/44 (59); 11/44 (25); 7/44 (16)	NVD (52); RD<1 (23) 𝑃=0.0007; >1 (20)
Güngör [18]	44	Surgery; chemo only; NVD	44/75 (59); 31/75 (41); 34/44 (77)	NVD (19); RD (9) 𝑃=0.007
Pfisterer [19]	267	NVD; RD<o>1 cm	133/267 (50); 69/267 (26); 65/267 (24)	NVD (45.3); RD (19) 𝑃<0.0001
Ayhan [20]	64	NVD; RD<o>1 cm	28/64 (44); 25/64 (39); 11/64 (17)	<1 (28); >1 (18) 𝑃=0.004

RD: residual disease, NVD: no visible disease, NS: not significant, NYR: not yet reached.